INDICATION

LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

LUMAKRAS has established broad coverage with 95% of patients covered nationally*

*Includes 93% commercial, 99% Medicare, 97% Managed Medicaid, and 94% State Medicaid coverage.

LUMAKRAS has established broad coverage with 95% of patients covered nationally*

*Includes 93% commercial, 99% Medicare, 97% Managed Medicaid, and 94% State Medicaid coverage.

Amgen®SupportPlus logo

We’re right here, right when you need us

Personalized support that you and your patients can count on across Amgen therapies.

Enroll your patients

Call Amgen® SupportPlus at 866-264-2778

Monday - Friday 8:00 am – 8:00 pm ET.

Visit AmgenSupportPlus.com to learn how Amgen can help.

LUMAKRAS® healthcare provider support center HCP Support Center

LUMAKRAS® healthcare provider support center

HCP Support Center

Our Amgen® SupportPlus Representatives can assist with issues around patient coverage, prior authorizations, co-pay programs, and more.

Benefits Verification

  • Verify patient’s insurance plan coverage details
  • Identify if there is a payer-mandated pharmacy for prescription fulfillment

Prior Authorization Requirements

  • Provide payer-specific prior authorization forms

Amgen SupportPlus Customer Portal

  • A tool for managing patient benefits verifications and more
  • Submit, store, and retrieve benefit verifications electronically

Amgen® Access SpecialistsAmgen® Access Specialists

Amgen® Access Specialists

Amgen® Access Specialists

An Access Specialist can provide live or virtual coverage and access resources to support your patients.

Contact your Access Specialist for live or virtual support that includes:

  • Help with navigating prior authorization, appeals, and fulfillment processes
  • Educating on payer requirements and necessary documentation for individual patient support
  • Guidance on general reimbursement questions, including product coding and billing information
  • Answers to general questions about Amgen SupportPlus programs and other available resources

Amgen® Nurse PartnersAmgen® Nurse Partners

Amgen® Nurse Partners

Amgen® Nurse Partners

Dedicated Amgen Nurse Partners can offer supplemental support to help your patients on their journey

Amgen Nurse Partners can provide supplemental support, including:

  • Guidance on resources that may help lower out-of-pocket medication costs
  • Assistance to help your patients stay on track with their medication
  • Answers to questions about Amgen SupportPlus

    Patients can connect with a dedicated Amgen Nurse Partner by enrolling in Amgen SupportPlus in two ways:

    • Download and complete the Amgen SupportPlus Enrollment Form found on AmgenSupportPlus.com and give it to your office to complete and fax to 1-866-218-4777
    • Call 866-264-2778 to enroll by phone

Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your patient’s treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Financial supportFinancial Support

Financial support

Financial Support

We know every patient has unique needs. And we’re here to provide financial support information and resources, regardless of their current financial situation or type of insurance they have.

What if my patient doesn’t have private or commercial insurance?

Amgen® SupportPlus can provide your patients with information about independent nonprofit foundations that may be able to help.

Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria.

Amgen has no control over these programs and provides information as a courtesy only.

Amgen®SupportPlus logo

Amgen® SupportPlus Co-Pay Program

The Amgen SupportPlus Co-Pay Program may help eligible patients with private or commercial insurance lower their out-of-pocket costs.

  • Pay as little as $0 out-of-pocket for each dose††
  • Can be applied to deductible, co-insurance and co-payment††
  • No income eligibility requirement

Visit Amgen SupportPlus now

††Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay for full Terms and Conditions.

Learn more about how Amgen SupportPlus can help your patients access their prescribed medication.

Call Amgen® SupportPlus at 866-264-2778

Monday - Friday 8:00 am – 8:00 pm ET to learn more.

Dispensing resources

Script fulfillment options

There are multiple ways for patients to receive LUMAKRAS, depending on their insurance. These options include national specialty pharmacies, dispensing oncology clinics, and others.

National specialty pharmacies

National specialty pharmacies

Oncology clinics

Oncology clinics

Distribution and dispensing resources

Download LUMAKRAS® resources

Pharmacy Fact Sheet

Download LUMAKRAS® resources

LUMAKRAS specialty
pharmacy and distributors list

Patient resources

Download LUMAKRAS® resources

Click here to download a
brochure for your patients

IMPORTANT SAFETY INFORMATION

Hepatotoxicity

  • LUMAKRAS can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis.
  • Among 357 patients who received LUMAKRAS in CodeBreaK 100, hepatotoxicity occurred in 1.7% (all grades) and 1.4% (Grade 3). A total of 18% of patients who received LUMAKRAS had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); 6% were Grade 3 and 0.6% were Grade 4. In addition to dose interruption or reduction, 5% of patients received corticosteroids for the treatment of hepatotoxicity.
  • Monitor liver function tests (ALT, AST, and total bilirubin) prior to the start of LUMAKRAS, every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations.
  • Withhold, dose reduce or permanently discontinue LUMAKRAS based on severity of adverse reaction.

Interstitial Lung Disease (ILD)/Pneumonitis

  • LUMAKRAS can cause ILD/pneumonitis that can be fatal. Among 357 patients who received LUMAKRAS in CodeBreaK 100 ILD/pneumonitis occurred in 0.8% of patients, all cases were Grade 3 or 4 at onset, and 1 case was fatal. LUMAKRAS was discontinued due to ILD/pneumonitis in 0.6% of patients.
  • Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold LUMAKRAS in patients with suspected ILD/pneumonitis and permanently discontinue LUMAKRAS if no other potential causes of ILD/pneumonitis are identified.

Most common adverse reactions

  • The most common adverse reactions ≥ 20% were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough.

Drug interactions

  • Advise patients to inform their healthcare provider of all concomitant medications, including prescription medicines, over‑the‑counter drugs, vitamins, dietary and herbal products.
  • Inform patients to avoid proton pump inhibitors and H2 receptor antagonists while taking LUMAKRAS.
  • If coadministration with an acid-reducing agent cannot be avoided, inform patients to take LUMAKRAS 4 hours before or 10 hours after a locally acting antacid.

INDICATION

LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC), as determined by an FDA‑approved test, who have received at least one prior systemic therapy.

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).


Please see full Prescribing Information.

Important Safety Information

Hepatotoxicity

  • LUMAKRAS can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis.
  • Among 357 patients who received LUMAKRAS in CodeBreaK 100, hepatotoxicity occurred in 1.7% (all grades) and 1.4% (Grade 3). A total of 18% of patients who received LUMAKRAS had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); 6% were Grade 3 and 0.6% were Grade 4. In addition to dose interruption or reduction, 5% of patients received corticosteroids for the treatment of hepatotoxicity.
  • Monitor liver function tests (ALT, AST, and total bilirubin) prior to the start of LUMAKRAS, every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations.
  • Withhold, dose reduce or permanently discontinue LUMAKRAS based on severity of adverse reaction.